Get the Stockscreener App
25.43
1.03%
0.26
After Hours:
25.45
0.02
+0.08%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.43, with a volume of 50.44M.
It is up +1.03% in the last 24 hours and down -2.31% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.17
Open:
$25.185
24h Volume:
50.44M
Relative Volume:
0.80
Market Cap:
$144.59B
Revenue:
$62.79B
Net Income/Loss:
$9.84B
P/E Ratio:
14.82
EPS:
1.7156
Net Cash Flow:
$10.38B
1W Performance:
+1.76%
1M Performance:
-2.31%
6M Performance:
+0.20%
1Y Performance:
-5.43%
1-Day Range:
$25.18
$26.00
1-Week Range:
$24.83
$26.00
52-Week Range:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.43 | 143.11B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,064.04 | 932.17B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.79 | 492.24B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.93 | 389.14B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
142.27 | 264.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.87 | 266.67B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Stock Plot Twist: Is This Big Pharma OG a Secret Comeback Play or Total Trap? - AD HOC NEWS
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Pfizer invested in this Peninsula biotech startup. Now they've cut a potentially big drug deal - The Business Journals
Cartography Biosciences And Pfizer To Collaborate On The Discovery Of Tumor-Selective Antigens - TradingView — Track All Markets
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens - Business Wire
Torray Investment Partners LLC Acquires 102,107 Shares of Pfizer Inc. $PFE - MarketBeat
Sulfasalazine Market Is Booming Worldwide 2026-2033 | Pfizer - openPR.com
Robeco Institutional Asset Management B.V. Has $290.44 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Phenobarbital Market See Incredible Growth 2025-2032 | Sanofi, Pfizer Inc., Novartis AG, H. Lundbeck A/S - openPR.com
Pfizer's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Gateway Investment Advisers LLC Lowers Stock Position in Pfizer Inc. $PFE - MarketBeat
Sleep Aids Market Booming with Rapid Growth Through 2033| Pfizer Inc., GSK plc, Sommetrics, Inc. - openPR.com
Pfizer’s 2026 Drug Price Reset Could Be A Game Changer For Pfizer (PFE) - simplywall.st
Pfizer (PFE) Stock: COVID-19 Revenue Decline Spurs Strategic Shift - parameter.io
Pfizer Inc. $PFE Position Cut by Commonwealth Equity Services LLC - MarketBeat
Motley Fool Money: Stock Market Naughty and Nice List - The Motley Fool
Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals - Finviz
Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Dividend Support - Yahoo! Finance Canada
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - Bluefield Daily Telegraph
Better dividend stock: Ford vs. Pfizer - MSN
D.A. Davidson & CO. Acquires 70,161 Shares of Pfizer Inc. $PFE - MarketBeat
Better Dividend Stock: Ford vs. Pfizer - Finviz
Daymark Wealth Partners LLC Sells 52,529 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Allen Wealth Management LLC - MarketBeat
Asset Management One Co. Ltd. Grows Position in Pfizer Inc. $PFE - MarketBeat
Capital Advisors Inc. OK Grows Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc Is On Clearance?! The Wild Truth Behind PFE’s Price Drop - AD HOC NEWS
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom - ts2.tech
Pfizer Ltd Is Having a Moment: Hype Stock or Just Hot Air? - AD HOC NEWS
Pfizer Inc. $PFE Shares Purchased by Verity & Verity LLC - MarketBeat
How Safe Is Pfizer's Dividend As 2026 Begins? - The Globe and Mail
Generali Asset Management SPA SGR Has $5.33 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Pfizer (NYSE:PFE) Trading 1.1% HigherShould You Buy? - MarketBeat
2 Predictions for Pfizer in 2026 - Finviz
Pfizer 2026: The Reset Year (NYSE:PFE) - Seeking Alpha
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching - ts2.tech
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus - ts2.tech
Pfizer (PFE) navigates patent losses with strategic cost controls, BMO Capital reaffirms outperform rating - MSN
Pfizer (PFE) Navigates Patent Losses With Strategic Cost Controls, BMO Capital Reaffirms Outperform Rating - Insider Monkey
Pfizer discloses death in long-term Hympavzi study after thrombotic stroke - The Pharma Letter
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure - BioSpace
Zacks Research Brokers Reduce Earnings Estimates for Pfizer - MarketBeat
Tectonic Advisors LLC Buys 49,737 Shares of Pfizer Inc. $PFE - MarketBeat
New Horizons in Vaccines Market to Boom Worldwide By 2025-2032 - openPR.com
Pfizer Inc.: From Pandemic Icon to Platform Powerhouse - AD HOC NEWS
This Pharma Company’s Gamble Might Finally Be Paying Off - Fortune Herald
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes - ts2.tech
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30 - FinancialContent
Should You Buy Pfizer While It's Under $30? - Finviz
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes - ts2.tech
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):